Text Size: SMALL  LARGE

13th Annual Angioma Alliance

CCM Scientific Meeting

Westin Georgetown, Washington, DC

October 26 & 27, 2017

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Day 1 | Thursday October 26, 2017

 

8:50    Welcome & Opening Remarks        

           

Session I - Lesion Genesis

           

9:00    Uncovering molecular pathways involved in cerebral cavernous malformations by pharmacological suppression

            Cecile Otten - Potsdam University

           

9:15    The role of Polycomb group Proteins in CCM pathology

            Matteo Malinverno, Institute of Molecular Oncology, Milan

           

9:30    Inactivation of RhoA-kinase in Ccm3+/- mice suggest a role for the RhoA-kinase pathway in CCM3-lesion genesis and maturation

            Amy Peiper -  Duke University

           

9:45    Thrombospondin1 (TSP1) controls development of cerebral cavernous malformations

            Miguel Alejandro Lopez-Ramirez -  University of California, San Diego

           

10:00  Endothelial TLR4 and the gut microbiome drive cerebral cavernous malformations

            Alan Tang - University of Pennsylvania

           

10:15  Vascular Endothelial Growth Factor is required for CCM lesion initiation

            Kevin Whitehead - University of Utah and Angela Glading - University of Rochester

           

10:30  Discussion

           

10:45  Break

 

Session II - CCM Protein function

 

11:00  A conserved CCM complex promotes apoptosis non-autonomously by regulating zinc homeostasis in C. elegans

            Eric Chapman - University of Toronto

           

11:15  KRIT1 loss-of-function induces a chronic Nrf2-mediated adaptive homeostasis that sensitizes cells to oxidative stress: Implications for Cerebral Cavernous Malformation disease

            Cinzia Antognelli - University of Perugia

           

11:30  The role of Ccm2l in Cerebral Cavernous Malformations in neonatal mouse brain

            Jaesung Choi - Centenary Institute, Sydney

           

11:45  CCM3 deficiency increases levels of multiple tyrosine kinase receptors

            Juan Zalvide - Universidade de Santiago de Compostela

           

12:00  Discussion

           

12:30  LUNCH

           

Session III - Clinical Management and Patient Reported Outcomes

 

1:30    Review of a Large Registry of Pediatric Familial CCM

            Leslie Morrison - University of New Mexico

           

1:45    Minimally Invasive Resection of Rolandic Cavernomas in Children using a Novel Navigable Tubular Retractor System

            Erin Kiehna

           

2:00    Mental Health Outcomes in Pediatric Cavernoma

            Tiffany Campbell - Cincinnati Children's Hospital Medical Center

           

2:15    Quality of Life Measures in Familial Cerebral Cavernous Malformation Patients

            Jeff Nelson - University of California San Francisco

           

2:30    Discussion

           

Poster Session (3 – 4:30)

 

Pathologic/Radiologic Correlation and Findings in fCCM Lesions in Different Tissues

Blaine Hart – University of New Mexico

 

Role of lamotrigine in management of commonly encountered symptoms in patients with cerebral cavernous malformations

Asad Ikram -  University of New Mexico

 

Exploring the ccm-3 Network

Benjamin Lant – The Hospital for Sick Children

 

The Baca Family Historical Project: Paradigm-Shifting Approach to Patient Engagement

Connie Lee – Angioma Alliance

 

Up-regulation of NAPH oxidase-mediated redox signaling contributes to the loss of barrier function in KRIT1 deficient endothelium

Nicholas Nobiletti – University of Rochester

 

The Effect of Gut Microbiome on Chronic Models of CCM Lesion Formation

Heidy Pardo – Duke University

 

Development of the pectoral fin vasculature in zebrafish embryos

Scott Paulissen – NIH/NICHD

 

Characterizing the role of RHOA in regulating cranial vascular integrity

Laura Pillay – NIH/NICHD

 

ROCK2-selective inhibitors and their effects on key features of the biology of cerebral cavernous malformations

Jörg Ruschel – BioAxone Biosciences

 

A Novel Perivascular Cell Population in the Zebrafish Brain

Marina Venero Galanternik – NIH/NICHD

 

Novel functions of CCM1 delimit the relationship of PTB/PH domains

Jun Zhang – Texas Tech University Health Sciences Center

           

4:30    Break

           

Dinner (7-9 PM)

Nick's Riverside Grill, 3050 K St NW, Washington, DC

           

           

 

Day 2 | Friday, October 27, 2017

 

Session IV - Cell Biology  

           

9:00    The Cerebral cavernous malformation disease causing gene KRIT1 participates in epithelial barrier maintenance and regulation

            Le Shen - University of Chicago

           

9:15    Glycolytic metabolism and VEGFR3 signaling are required for lymphangiogenesis

            Joanne Chan - Hamilton University

           

9:30    Molecular regulation of vascular smooth muscle cell recruitment to arteries during development

            Amber Stratman – NIH/NICHD

           

9:45    Discussion

           

10:00  Keynote address

            Victoria Bautch - University of North Carolina at Chapel Hill

           

10:45  Break

           

11:00  Angioma Alliance Updates

            Connie Lee - Angioma Alliance

           

11:15  Panel Discussion – Pediatric CCM: Special Considerations for Treatment and Trials

Moderator

Ed Smith, MD – Director Pediatric Cerebrovascular Neurosurgery, Boston Children’s

Panelists

Barry Mangum, PharmD - CEO Paidion Research, Inc (Trial Design Considerations)

Ronald Farkas MD PhD - Vice President PAREXEL International (Regulatory Considerations)

Sudhakar Vadivelu, MD - Cincinnati Children’s Hospital and Medical Center (Clinical Management)

           

12:30  Lunch

           

Session V - Clinical Trial Readiness

           

1:30    Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth

            Romuald Girard - University of Chicago

           

1:45    Developing a new drug for CCM: the path from bench to bedside

            Ken Rosen - BioAxone BioSciences

           

2:00    Recent Developments in Advancing Tempol as a Treatment for CCM

            Tim Considine - Recursion Pharmaceuticals

           

2:15    CASH (Cavernous Angiomas with Symptomatic Hemorrhage) Trial Readiness

            Sean Polster – University of Chicago

           

2:30    Discussion

           

2:45    2017 CCM Meeting Summary and Closing Remarks

            Issam Awad - University of Chicago

           

3:00    Close of Meeting